Replimune Group, Inc.

REPL Nasdaq SEC CIK 1737953
Follow Replimune Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2027 USD · US GAAP
Net income −$57.1M +31.3% vs same quarter last year
EPS, diluted −$0.54 +40% vs same quarter last year
Operating cash flow −$47.7M +41.3% vs same quarter last year
Operating income −$56.3M +33.2% vs same quarter last year
Net income by quarter
−$66.3M
−$74.1M
−$86.7M
−$83.1M
−$70.9M
−$73.2M
−$69.8M
−$57.1M
Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
−$400M−$300M−$200M−$100M$0FY18FY20FY22FY24FY26
Show the numbers
YearNet income
FY26−$313.9M
FY25−$247.3M
FY24−$215.8M
FY23−$174.3M
FY22−$118M
FY21−$80.9M
FY20−$52.6M
FY19−$30.8M
FY18−$19.7M
FY17−$7.7M
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY18FY20FY22FY24FY26
Show the numbers
YearFree cash flow
FY26−$284.6M
FY25−$198.9M
FY24−$191.1M
FY23−$130.3M
FY22−$84.5M
FY21−$63.8M
FY20−$67.1M
FY19−$28M
FY18−$16.2M
FY17−$7.3M